Keep An Eye On Intellia Therapeutics As Insider Stock Selling Hits US$1.5m
Keep An Eye On Intellia Therapeutics As Insider Stock Selling Hits US$1.5m
While Intellia Therapeutics, Inc. (NASDAQ:NTLA) shareholders have had a good week with the stock up 12%, they shouldn't let their guards down. The fact that insiders chose to dispose of US$1.5m worth of stock in the past 12 months even though prices were relatively low could be indicative of some anticipated weakness.
尽管Intellia Therapeutics, Inc.(纳斯达克股票代码:NTLA)的股东度过了愉快的一周,该股上涨了12%,但他们不应放松警惕。尽管价格相对较低,但内部人士在过去12个月中还是选择出售价值150万美元的股票,这一事实可能表明一些预期的疲软。
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares.
虽然我们绝不会建议投资者仅根据公司董事的所作所为做出决定,但逻辑要求你应该注意内部人士是在买入还是卖出股票。
Intellia Therapeutics Insider Transactions Over The Last Year
去年 Intellia Therapeutics 的内幕交易
In the last twelve months, the biggest single sale by an insider was when the President, John Leonard, sold US$566k worth of shares at a price of US$29.46 per share. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. The good news is that this large sale was at well above current price of US$26.57. So it may not shed much light on insider confidence at current levels.
在过去的十二个月中,内部人士最大的一次出售是总裁约翰·伦纳德以每股29.46美元的价格出售了价值56.6万美元的股票。我们通常不喜欢看到内幕销售,但是销售价格越低,我们就越担心。好消息是,此次大宗销售远高于当前的26.57美元。因此,在当前水平上,这可能无法为内部信心提供太多启示。
In the last year Intellia Therapeutics insiders didn't buy any company stock. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
去年,Intellia Therapeutics内部人士没有购买任何公司股票。你可以在下面看到过去 12 个月内幕交易(公司和个人)的直观描述。如果你想确切地知道谁卖了、卖了多少以及何时出售,只需点击下图!
![insider-trading-volume](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240207/0-c4ab859061bdf9ddb7be42748f18f8aa-0-6a78de1f2bd378f0d7e2082f65e0427e.png/big)
For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
对于那些喜欢寻找中奖投资的人来说,这份最近有内幕收购的成长型公司的免费名单可能只是门票。
Intellia Therapeutics Insiders Are Selling The Stock
Intellia Therapeutics 内部人士正在出售该股
Over the last three months, we've seen significant insider selling at Intellia Therapeutics. In total, insiders sold US$1.4m worth of shares in that time, and we didn't record any purchases whatsoever. This may suggest that some insiders think that the shares are not cheap.
在过去的三个月中,我们看到了Intellia Therapeutics的大量内幕抛售。在此期间,内部人士总共出售了价值140万美元的股票,我们没有记录任何购买记录。这可能表明一些内部人士认为股票并不便宜。
Insider Ownership
内部所有权
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. Insiders own 1.4% of Intellia Therapeutics shares, worth about US$34m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
测试公司领导者与其他股东之间一致性的另一种方法是查看他们拥有多少股份。较高的内部所有权通常会使公司领导层更加关注股东的利益。业内人士拥有Intellia Therapeutics1.4%的股份,价值约3400万美元。当然,我们在其他地方看到了更高的内部所有权水平,但这些持股足以表明内部人士与其他股东之间的一致性。
So What Do The Intellia Therapeutics Insider Transactions Indicate?
那么,Intellia Therapeutics的内幕交易表明了什么呢?
Insiders sold stock recently, but they haven't been buying. And even if we look at the last year, we didn't see any purchases. Insider ownership isn't particularly high, so this analysis makes us cautious about the company. We'd practice some caution before buying! So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. At Simply Wall St, we found 3 warning signs for Intellia Therapeutics that deserve your attention before buying any shares.
内部人士最近出售了股票,但他们一直没有买入。而且,即使我们看看去年,我们也没有看到任何购买。内部所有权并不是特别高,因此这种分析使我们对公司持谨慎态度。购买前我们会谨慎行事!因此,这些内幕交易可以帮助我们建立有关股票的论点,但也值得了解该公司面临的风险。在Simply Wall St,我们发现了Intellia Therapeutics的3个警告信号,在购买任何股票之前,值得你注意。
But note: Intellia Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
但请注意:Intellia Therapeutics可能不是最值得购买的股票。因此,来看看这份投资回报率高、债务低的有趣公司的免费清单。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,内部人士是指向相关监管机构报告其交易的个人。我们目前只考虑公开市场交易和私下处置的直接利益,不包括衍生品交易或间接权益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。